Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.

abstract：:Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

journal_title：Leukemia & lymphoma

authors： Piggin A,Bayly E,Tam CS

更新日期：2017-06-01 00:00:00

abstract：:The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

journal_title：Leukemia & lymphoma

authors： Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

更新日期：1996-04-01 00:00:00

abstract：:Rituximab is a CD20-targeted monoclonal antibody widely used in the treatment of B-cell lymphoma. Previously, we have shown that Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) increases chemoresistance in malignant cancer cells. In this study we examined the effects of LMP1 on the response of B-cell lymphom...

journal_title：Leukemia & lymphoma

authors： Kim JH,Kim WS,Park C

更新日期：2012-08-01 00:00:00

abstract：:Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

journal_title：Leukemia & lymphoma

authors： Bhatt VR,Gundabolu K,Koll T,Maness LJ

更新日期：2018-01-01 00:00:00

abstract：:Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

journal_title：Leukemia & lymphoma

authors： Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

更新日期：2012-10-01 00:00:00

abstract：:The Philadelphia chromosome, arising as a consequence of the t(9;22) translocation, is one of the most frequent and certainly the most known cytogenetic abnormality present in human hematological malignancies. Unlike the vast majority of the other translocations, its presence is not restricted to a specific leukemia p...

journal_title：Leukemia & lymphoma

authors： Saglio G,Pane F,Martinelli G,Guerrasio A

更新日期：1997-07-01 00:00:00

abstract：:Castleman's disease is a rare condition characterized by benign hyperplastic lymph nodes. Based on the morphological features, it has been divided into hyaline-vascular, plasma cell and intermediate types. The latter two types are frequently associated with a wide variety of clinical pictures such as fever, anemia wit...

journal_title：Leukemia & lymphoma

authors： Yabuhara A,Komiyama A

更新日期：1990-01-01 00:00:00

abstract：:The role of cyclic AMP (cAMP) as second messenger in erythropoiesis has been suggested in the early 1980s. However, careful analysis showed that cAMP is not generated in direct response to the main erythropoiesis-controlling cytokines such as erythropoietin (Epo). As a result, cAMP disappeared from the central stage i...

journal_title：Leukemia & lymphoma

authors： Boer AK,Drayer AL,Vellenga E

更新日期：2003-11-01 00:00:00

abstract：:A patient with primary biliary cirrhosis (PBC) who developed idiopathic myelofibrosis (IM) is reported. The initial diagnosis of PBC was established by liver biopsy, performed after a 2-month history of constitutional symptoms associated with abnormalities of the serum liver enzymes, with typical serum immunological m...

journal_title：Leukemia & lymphoma

authors： Hernández-Boluda JC,Jiménez M,Rosiñol L,Cervantes F

更新日期：2002-03-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:Telomerase, an enzyme associated with cellular immortality, is expressed on malignant tumor cells. Deregulation of telomerase is thought to facilitate tumorigenesis and cellular immortality by providing cancer cells with unlimited proliferation capacity. Hodgkin and Reed-Sternberg (H&RS) cells are generally considered...

journal_title：Leukemia & lymphoma

authors： Ohshima K,Sugihara M,Haraoka S,Suzumiya J,Kanda M,Kawasaki C,Shimazaki K,Kikuchi M

更新日期：2001-04-01 00:00:00

abstract：:Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

journal_title：Leukemia & lymphoma

authors： Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

更新日期：2008-01-01 00:00:00

abstract：:To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

journal_title：Leukemia & lymphoma

authors： Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

更新日期：2014-06-01 00:00:00

abstract：:Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

journal_title：Leukemia & lymphoma

authors： Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

更新日期：2010-06-01 00:00:00

abstract：:Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

journal_title：Leukemia & lymphoma

authors： Sever M,Newberry KJ,Verstovsek S

更新日期：2014-12-01 00:00:00

abstract：:There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...

journal_title：Leukemia & lymphoma

authors： Lee HK,Wilder RB,Jones D,Ha CS,Pro B,Rodriguez MA,Romaguera JE,Cabanillas F,Rodriguez J,Cox JD

更新日期：2002-09-01 00:00:00

abstract：:The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians worki...

journal_title：Leukemia & lymphoma

authors： Bruno B,Auner HW,Gahrton G,Garderet L,Festuccia M,Ladetto M,Lemoli RM,Massaia M,Morris C,Palumbo A,Schönland S,Boccadoro M,Kröger N

更新日期：2016-01-01 00:00:00

abstract：:Among 318 cases of non-Hodgkin's lymphoma (NHL) treated in our unit, 145 (45.6%) had primary extranodal NHL (PE-NHL). The stomach was the most common site (42.1%), followed by the PE-NHL of the head and neck region. Histologically aggressive histologies (65.5% intermediate and 20.7% high grade) predominated. 89.6% of ...

journal_title：Leukemia & lymphoma

authors： Economopoulos T,Asprou N,Stathakis N,Papageorgiou E,Dervenoulas J,Xanthaki K,Raptis S

更新日期：1996-03-01 00:00:00

abstract：:Thalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indir...

journal_title：Leukemia & lymphoma

authors： Vallet S,Palumbo A,Raje N,Boccadoro M,Anderson KC

更新日期：2008-07-01 00:00:00

abstract：:Sensitivity to doxorubicin (DOX) and expression of intracellular endogenous TNF (enTNF) or manganous superoxide dismutase (MnSOD) activity were found to be inversely correlated in leukemic cells from 19 patients (6 acute lymphoblastic leukemia, 13 acute myeloblastic leukemia). In a case with acquired resistance to che...

journal_title：Leukemia & lymphoma

authors： Watanabe N

更新日期：1998-08-01 00:00:00

abstract：:Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias...

journal_title：Leukemia & lymphoma

authors： Bose P,Verstovsek S

更新日期：2020-08-01 00:00:00

abstract：:A methodology for selection of the CD8 cell subset from the peripheral blood and bone marrow mononuclear cells was developed using anti-T8 (CD8) antibody and magnetic microspheres coated with anti-mouse IgG. Following optimization of antibody:cell binding ratio and microsphere:cell ratios, CD8(+)-cells in the peripher...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,He YJ

更新日期：1992-09-01 00:00:00

abstract：:Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...

journal_title：Leukemia & lymphoma

authors： Gandhi V,Estey E,Keating MJ,Plunkett W

更新日期：1993-01-01 00:00:00

abstract：:Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent a...

journal_title：Leukemia & lymphoma

authors： Goebeler ME,Bargou R

更新日期：2016-05-01 00:00:00

abstract：:Out of 75 consecutive elderly AML patients who did not receive anti-leukemic treatment (52 pts) or failed to respond to differentiating agent (23 pts), 6 patients had survivals of 13.2 to 98 months with treatment restricted to supportive care. This cut-point is far longer than the median survival of the 235 elderly pa...

journal_title：Leukemia & lymphoma

authors： Baudard M,Legrand O,Marie JP,Zittoun R

更新日期：1999-08-01 00:00:00

abstract：:The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymp...

journal_title：Leukemia & lymphoma

authors： Segman Y,Ribakovsky E,Avigdor A,Goldhecht Y,Vainstein V,Goldschmidt N,Harlev S,Horwitz N,Gutwein O,Gurion R,Itchaki G,Abadi U,Nemets A,Sofer O,Zektser M,Tadmor T,Dally N,Filanovsky K,Leiba M,Sarid N,Benyamini N,

更新日期：2021-01-01 00:00:00

abstract：:We investigated the role of the leptin receptor (Ob-R) and its relationship with PI3K/AKT activation in diffuse large B-cell lymphoma (DLBCL) clinical samples followed by in vitro studies using a panel of CRC cell lines. Leptin exerts its physiological action through its receptor Ob-R. Overexpression of Ob-R has been ...

journal_title：Leukemia & lymphoma

authors： Uddin S,Bu R,Ahmed M,Hussain AR,Ajarim D,Al-Dayel F,Bavi P,Al-kuraya KS

更新日期：2010-07-01 00:00:00

abstract：:This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive ste...

journal_title：Leukemia & lymphoma

authors： Drach J,Huang H,Samoilova O,Belch A,Farber C,Bosly A,Novak J,Zaucha J,Dascalescu A,Bunworasate U,Masliak Z,Vilchevskaya K,Robak T,Pei L,Rooney B,van de Velde H,Cavalli F

更新日期：2018-04-01 00:00:00

abstract：:The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early consolidation usin...

journal_title：Leukemia & lymphoma

authors： Jehn U

更新日期：1994-09-01 00:00:00

abstract：:Triptolide is a diterpenoid triepoxide purified from a Chinese herb Tripterygium Wilfordii Hook F (TWHF). TWHF has been used in traditional Chinese medicine for more than two thousand years. However, its potential value was recognized by the western medicine only after investigators observed the effectiveness of TWHF ...

journal_title：Leukemia & lymphoma

authors： Chen BJ

更新日期：2001-07-01 00:00:00